I see JR JN revised his revenue guidance to 20 million, that should get JP complaining about something else? While I like Jason's enthusiasm he really has no clue! I say sell it and get on with the human trials in MANF...
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links
